Infertility infertility
Conditions
Interventions
Pterostilbene or placebo is administered daily for a period of 6 to 10 weeks (1 capsule/tablet twice daily after breakfast and dinner) starting 1 week before the start of menstruation.
Sponsors
Kawamura Kazuhiro
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: (1) Infertile female patients undergoing in vitro fertilization. (2) Patients aged 40 years or older at the time of informed consent . (3) Patients attending the outpatient clinic of a collaborating study site. (4) Patients who have the ability to consent and are able to obtain written consent by their own volition. (5) Patients judged by the investigator (co-investigator) to be able to appropriately evaluate the efficacy and safety of this study with considering the inclusion and exclusion criteria.
Exclusion criteria
Exclusion criteria: (1) Patients taking supplements other than vitamins, minerals, and beta-carotene within one menstrual cycle prior to randomization. (2) Patients where the possible causes of infertility include diabetes mellitus, polycystic ovary, or a partner with severe spermatogenic dysfunction. (3) Patients who have received reproductively toxic chemotherapy or radiotherapy. (4) Patients with recurrent implantation failure. (5) Unmarried patients who wish to freeze their eggs. (6) Patients who have participated in this study in the past. (7) Patients with an allergy to resveratrols and dextrin (starch). (8) Patients with a menstrual cycle of 3 weeks or less or 5 weeks or more. (9)Patients who are considered inappropriate for participation in the study by the investigator or subinvestigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of embryos reaching the blastocyst stage on Day 5 after fertilization (number of blastocysts/ number of normal fertilized oocytes) | — |
Secondary
| Measure | Time frame |
|---|---|
| Oocyte maturation rate (number of mature oocytes/number of retrieved oocytes) Fertilization rate (number of normal fertilized oocytes/number of retrieved oocytes) Clinical pregnancy rate (frequency of detectable gestational sac under ultrasound analysis/frequency of embryo transfer) Miscarriage rate (frequency of miscarriage/frequency of embryo transfer) Pterostilbene concentration (blood and follicular fluid) | — |
Contacts
Public ContactKazuhiro Kawamura
Juntendo University Hospital
Outcome results
None listed